NCT07488780 Language Network Prehab Via fMRI Neurofeedback
| NCT ID | NCT07488780 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 4 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4 participants in total. It began in 2026-08-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an interventional neuroimaging study that will examine whether fMRI neurofeedback can shift language network activity away from regions affected by glioma prior to surgery.
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Diagnosis of WHO grade II-III glioma involving eloquent language cortex * Scheduled for surgical resection * MRI-compatible * Ability to perform the simple language tasks required for fMRI and neurofeedback * Residence within 2 hours of Yale MRRC and ability and willingness to make multiple visits for study participation Exclusion Criteria: * Severe baseline aphasia precluding task performance * Contraindications to MRI * Significant cognitive/psychiatric comorbidity limiting compliance * Concurrent enrollment in other interventional trials * Claustrophobia of a degree that they cannot comfortably be scanned * Inability or unwillingness to understand or follow the instructions * Pregnancy or possible pregnancy
Contact & Investigator
Luca Pasquini, MD, PhD
PRINCIPAL INVESTIGATOR
Yale School of Medicin
Frequently Asked Questions
Who can join the NCT07488780 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07488780 currently recruiting?
Yes, NCT07488780 is actively recruiting participants. Contact the research team at luca.pasquini@yale.edu for enrollment information.
Where is the NCT07488780 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07488780 clinical trial?
NCT07488780 is sponsored by Yale University. The principal investigator is Luca Pasquini, MD, PhD at Yale School of Medicin. The trial plans to enroll 4 participants.